331 related articles for article (PubMed ID: 35154100)
1. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
Wang H; Xie L; Song X; Wang J; Li X; Lin Z; Su T; Liang B; Huang D
Front Immunol; 2022; 13():773001. PubMed ID: 35154100
[TBL] [Abstract][Full Text] [Related]
2. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities.
Harmon DB; Mandler WK; Sipula IJ; Dedousis N; Lewis SE; Eckels JT; Du J; Wang Y; Huckestein BR; Pagano PJ; Cifuentes-Pagano E; Homanics GE; Van't Erve TJ; Stefanovic-Racic M; Jurczak MJ; O'Doherty RM; Kelley EE
Diabetes; 2019 Jun; 68(6):1221-1229. PubMed ID: 30936145
[TBL] [Abstract][Full Text] [Related]
5. Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease.
Shimizu M; Naito R; Sato A; Ishiwata S; Yatsu S; Shitara J; Matsumoto H; Murata A; Kato T; Suda S; Hiki M; Kuwabara M; Murase T; Nakamura T; Kasai T
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892555
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidoreductase activity in marathon runners: potential implications for marathon-induced acute kidney injury.
Kosaki K; Kumamoto S; Tokinoya K; Yoshida Y; Sugaya T; Murase T; Akari S; Nakamura T; Nabekura Y; Takekoshi K; Maeda S
J Appl Physiol (1985); 2022 Jul; 133(1):1-10. PubMed ID: 35608201
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.
Agarwal A; Banerjee A; Banerjee UC
Crit Rev Biotechnol; 2011 Sep; 31(3):264-80. PubMed ID: 21774633
[TBL] [Abstract][Full Text] [Related]
8. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.
Ohtsubo T; Matsumura K; Sakagami K; Fujii K; Tsuruya K; Noguchi H; Rovira II; Finkel T; Iida M
Hypertension; 2009 Oct; 54(4):868-76. PubMed ID: 19667249
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: Preliminary in vitro studies with analogues of immucillin-G.
Jacomelli G; Baldini E; Mugnaini C; Micheli V; Bernardini G; Santucci A
J Inherit Metab Dis; 2019 Jan; 42(1):178-185. PubMed ID: 30740729
[TBL] [Abstract][Full Text] [Related]
10. Xanthine oxidoreductase in cancer: more than a differentiation marker.
Battelli MG; Polito L; Bortolotti M; Bolognesi A
Cancer Med; 2016 Mar; 5(3):546-57. PubMed ID: 26687331
[TBL] [Abstract][Full Text] [Related]
11. The double faced role of xanthine oxidoreductase in cancer.
Chen MM; Meng LH
Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
[TBL] [Abstract][Full Text] [Related]
12. Arxula adeninivorans xanthine oxidoreductase and its application in the production of food with low purine content.
Jankowska DA; Trautwein-Schult A; Cordes A; Hoferichter P; Klein C; Bode R; Baronian K; Kunze G
J Appl Microbiol; 2013 Sep; 115(3):796-807. PubMed ID: 23773263
[TBL] [Abstract][Full Text] [Related]
13. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
Kelley EE
Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
16. Uric acid secretion from adipose tissue and its increase in obesity.
Tsushima Y; Nishizawa H; Tochino Y; Nakatsuji H; Sekimoto R; Nagao H; Shirakura T; Kato K; Imaizumi K; Takahashi H; Tamura M; Maeda N; Funahashi T; Shimomura I
J Biol Chem; 2013 Sep; 288(38):27138-27149. PubMed ID: 23913681
[TBL] [Abstract][Full Text] [Related]
17. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidoreductase mediates genotoxic drug-induced autophagy and apoptosis resistance by uric acid accumulation and TGF-β-activated kinase 1 (TAK1) activation.
Wang J; Hu Y; Liu P; Xu X
FASEB J; 2023 Feb; 37(2):e22723. PubMed ID: 36583708
[TBL] [Abstract][Full Text] [Related]
19. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
20. Natural mutations of human XDH promote the nitrite (NO
Massimo G; Khambata RS; Chapman T; Birchall K; Raimondi C; Shabbir A; Dyson N; Rathod KS; Borghi C; Ahluwalia A
Redox Biol; 2023 Nov; 67():102864. PubMed ID: 37713777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
